Origin Therapeutics
- Company typePrivate
- Founded2019
- HeadquartersVancouver, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
Origin Therapeutics firmographics
Firmographics- Name
- Origin Therapeutics
- Website
- https://originpsychedelics.com
- Company type
- Private
- Founded year
- 2019
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Origin Therapeutics industry classification
Industry- Product category
- Psychedelic Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- Translational Medicine & Biomarkers (HLAIALAF), Small-Molecule API Process Development & Route Scouting (HLAGAHAA)
Keywords
Where Origin Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Markets served
Origin Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Origin Therapeutics product offering
Product offeringCore offering
Origin Therapeutics operates the domain originpsychedelics.com, suggesting a focus on psychedelic-based therapeutic products or treatments. No substantive details about products, services, target indications, or scientific approach are available because the source content is limited to a verification/loading page with no further information.
Differentiator
Problem solved
Functional benefit
Origin Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Origin Therapeutics competitors and assessment
Company assessmentDirect peers
- Beckley Psytech: Private psychedelic drug-development company focused on intranasal and synthetic psychedelic candidates; comparable emerging-player psychedelic pipeline.
- Compass Pathways: Clinical-stage developer of psilocybin-based therapies for treatment-resistant depression; directly comparable psychedelic therapeutics peer pursuing regulated drug development.
- atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic candidates for mental health; overlapping therapeutic targets and modality.
- Cybin: Developer of psilocybin and deuterated psychedelic analogs for depression and addiction; comparable psychedelic small-molecule therapeutics approach.
- Filament Health: Developer of naturally-derived botanical psychedelic drug candidates; comparable psychedelic drug discovery and development focus.
- Mind Medicine (MindMed): Public psychedelic medicine developer with a pipeline spanning LSD, MDMA, and psilocybin candidates; comparable therapeutic focus and regulatory pathway.
- GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT) for treatment-resistant depression; directly comparable psychedelic therapeutics focus.
Emerging players
- Silo Pharma: Early-stage developer of psychedelic and CNS therapeutics; comparable emerging psychedelic therapeutics profile.
Broad incumbents
- Field Trip Health: Operated ketamine-assisted therapy clinics and pursued psychedelic drug development; broader psychedelic mental-health platform with overlapping therapeutic focus.
Others
- Pharmacotherapy for substance-use disorders (NIDA / academic) developers: Academic and government research programs investigating psychedelic compounds for addiction and mental-health indications; thematically related to psychedelic therapeutics R&D.
Market position
Strengths2 records
Weaknesses3 records
Key risks3 records
Key highlights2 records
Customer concentration
Origin Therapeutics social profiles
Digital presenceOrigin Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Origin Therapeutics leadership team
Management profileNumber of profiles
Origin Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Origin Therapeutics M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Origin Therapeutics
What does Origin Therapeutics do?
Origin Therapeutics operates the domain originpsychedelics.com, suggesting a focus on psychedelic-based therapeutic products or treatments. No substantive details about products, services, target indications, or scientific approach are available because the source content is limited to a verification/loading page with no further information.
When was Origin Therapeutics founded?
Origin Therapeutics was founded in 2019. It employs 1 to 10 people.
Where is Origin Therapeutics based?
Origin Therapeutics is headquartered in Vancouver, Canada, in the North America region.
Who are Origin Therapeutics's main competitors?
Direct peers on record are Beckley Psytech, Compass Pathways, atai Life Sciences, Cybin, Filament Health, Mind Medicine (MindMed) and GH Research. Silo Pharma is listed as an emerging player. Field Trip Health is listed as a broad incumbent. Pharmacotherapy for substance-use disorders (NIDA / academic) developers is listed as an others.
Does Origin Therapeutics have an API?
No public API is recorded for Origin Therapeutics.
What industry is Origin Therapeutics in?
Origin Therapeutics's product category is Psychedelic Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 3254 and its SIC code is 2834.